AstraZeneca Investor Conference Presentation Deck

11 2022: An incredible year of clinical success Exceptional delivery of best-in-industry pipeline Positive Phase III data readouts, selected Enhertu DESTINY-Breast04 HER2-low breast cancer eplontersen - NEURO-TTRansform ATTRv-PN Lynparza - OlympiA early breast cancer (US, EU, JP) Regulatory approvals in major markets, including: Ultomiris - CHAMPION-MG gMG (US, EU, JP) Enhertu - DESTINY-Breast04 HER2-low breast cancer (US) Beyfortus - MELODY/MEDLEY RSV (EU) Tezspire - NAVIGATOR severe asthma (EU, JP) Ultomiris - CHAMPION-NMOSD neuromyelitis optica spectrum disorder Imfinzi/Imjudo - HIMALAYA unresectable liver cancer (US, JP) danicopan - ALPHA PNH with clinically significant EVH Lynparza - PROpel metastatic CRPC (EU) Evusheld-PROVENT/TACKLE COVID-19 prevention/treatment (EU, JP) Enhertu - DESTINY-Breast03 HER2-positive breast cancer (US, EU) Enhertu - DESTINY-Lung02 HER2-low breast cancer (US) Imfinzi - TOPAZ-1 biliary tract cancer (US, EU, JP) Lynparza - PAOLA-1 HRD-positive ovarian cancer (CN) Soliris - PNH and aHUS (CN) Farxiga - DELIVER HFpEF Imfinzi - POSEIDON NSCLC (JP) capivasertib - CAPItello-291 advanced breast cancer Ondexxya - ANNEXA-4 acute major bleeds (JP) Saphnelo - MUSE/TULIP1&2 lupus (EU) Enhertu - DESTINY-Gastric01/02 gastric cancer (EU) Calquence ELEVATE-TN CLL (JP) HER2-low = human epidermal growth factor receptor 2-low; NMOSD neuromyelitis optica spectrum disorder; HFpEF = heart failure with preserved ejection faction; ATTRv-PN = hereditary transthyretin-mediated amyloid polyneuropathy; PNH = paroxysmal nocturnal haemoglobinuria; EVH = extravascular haemolysis; gMG = generalised yasthenia gravis; HER2-positive = human epidermal growth factor receptor 2-positive; EGFRm = epidermal growth factor receptor mutated; RSV = respiratory syncytial virus; HRD-positive = homologous recombination deficiency-positive; NF1 = neurofibromatos type 1; PN = plexiform neurofibromas; aHUS = atypical haemolytic uraemic syndrome; CRPC = castrate-resistant cancer; chronic lymphocytic leukaemia; CLL = chronic lymphocytic leukaemia. Collaboration partners: Merck (Lynparza, Koselugo), Daiichi Sankyo (Enhetu), Sanofi (Beyfortus), Amgen (Teszpire). Tagrisso - ADAURA early EGFRm lung cancer (JP) Forxiga - DAPA-CKD chronic kidney disease (CN) Koselugo - SPRINT NF1-PN (JP)

View entire presentation